101 related articles for article (PubMed ID: 20091273)
1. Design of pH-independent extended release matrix tablets of minocycline hydrochloride for the treatment of dementia.
Cha KH; Park J; Cho W; Gu DG; Jeong K; Hwang SJ
Arch Pharm Res; 2009 Nov; 32(11):1593-8. PubMed ID: 20091273
[TBL] [Abstract][Full Text] [Related]
2. pH-independent sustained release matrix tablet containing doxazosin mesylate: effect of citric acid.
Cha KH; Tran TH; Kim MS; Kim JS; Park HJ; Park J; Cho W; Hwang SJ
Arch Pharm Res; 2010 Dec; 33(12):2003-9. PubMed ID: 21191766
[TBL] [Abstract][Full Text] [Related]
3. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets.
Ceballos A; Cirri M; Maestrelli F; Corti G; Mura P
Farmaco; 2005; 60(11-12):913-8. PubMed ID: 16129436
[TBL] [Abstract][Full Text] [Related]
4. Eudragit-S, Eudragit-L and cellulose acetate phthalate coated polysaccharide tablets for colonic targeted delivery of azathioprine.
Kotagale N; Maniyar M; Somvanshi S; Umekar M; Patel CJ
Pharm Dev Technol; 2010; 15(4):431-7. PubMed ID: 20236031
[TBL] [Abstract][Full Text] [Related]
5. Extended release of a large amount of highly water-soluble diltiazem hydrochloride by utilizing counter polymer in polyethylene oxides (PEO)/polyethylene glycol (PEG) matrix tablets.
Kojima H; Yoshihara K; Sawada T; Kondo H; Sako K
Eur J Pharm Biopharm; 2008 Oct; 70(2):556-62. PubMed ID: 18606223
[TBL] [Abstract][Full Text] [Related]
6. Design and in vitro evaluation of novel sustained- release matrix tablets for lornoxicam based on the combination of hydrophilic matrix formers and basic pH-modifiers.
Hamza Yel-S; Aburahma MH
Pharm Dev Technol; 2010; 15(2):139-53. PubMed ID: 19895367
[TBL] [Abstract][Full Text] [Related]
7. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen.
Cao QR; Choi YW; Cui JH; Lee BJ
J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656
[TBL] [Abstract][Full Text] [Related]
8. Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug.
Kranz H; Guthmann C; Wagner T; Lipp R; Reinhard J
Eur J Pharm Sci; 2005 Sep; 26(1):47-53. PubMed ID: 15953712
[TBL] [Abstract][Full Text] [Related]
9. Optimization and characterization of a pH-independent extended-release hydrophilic matrix tablet.
Timmins P; Delargy AM; Howard JR
Pharm Dev Technol; 1997 Feb; 2(1):25-31. PubMed ID: 9552428
[TBL] [Abstract][Full Text] [Related]
10. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations.
Riis T; Bauer-Brandl A; Wagner T; Kranz H
Eur J Pharm Biopharm; 2007 Jan; 65(1):78-84. PubMed ID: 16919924
[TBL] [Abstract][Full Text] [Related]
11. Formulation of intelligent tablets with an antacid effect.
Bajdik J; Korbely A; Pintye-Hódi K
Pharm Dev Technol; 2009; 14(5):471-5. PubMed ID: 19552554
[TBL] [Abstract][Full Text] [Related]
12. [The control of drug release of heavy-soluble, weak basic drugs in matrix tablets using the example of medazepam].
Zessin G; Fahr F; Mank R
Pharmazie; 1986 Jan; 41(1):39-42. PubMed ID: 2870512
[TBL] [Abstract][Full Text] [Related]
13. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery.
Akhgari A; Afrasiabi Garekani H; Sadeghi F; Azimaie M
Int J Pharm; 2005 Nov; 305(1-2):22-30. PubMed ID: 16236475
[TBL] [Abstract][Full Text] [Related]
14. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
[TBL] [Abstract][Full Text] [Related]
15. Development of a multi particulate extended release formulation for ZK 811 752, a weakly basic drug.
Kranz H; Le Brun V; Wagner T
Int J Pharm; 2005 Aug; 299(1-2):84-91. PubMed ID: 15970409
[TBL] [Abstract][Full Text] [Related]
16. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
Sauer D; Zheng W; Coots LB; McGinity JW
Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
[TBL] [Abstract][Full Text] [Related]
17. Modulation of drug release kinetics of shellac-based matrix tablets by in-situ polymerization through annealing process.
Limmatvapirat S; Limmatvapirat C; Puttipipatkhachorn S; Nunthanid J; Luangtana-anan M; Sriamornsak P
Eur J Pharm Biopharm; 2008 Aug; 69(3):1004-13. PubMed ID: 18362064
[TBL] [Abstract][Full Text] [Related]
18. Microenvironmental pH and microviscosity inside pH-controlled matrix tablets: an EPR imaging study.
Siepe S; Herrmann W; Borchert HH; Lueckel B; Kramer A; Ries A; Gurny R
J Control Release; 2006 May; 112(1):72-8. PubMed ID: 16476499
[TBL] [Abstract][Full Text] [Related]
19. Hot melt granulation: a facile approach for monolithic osmotic release tablets.
Panda RR; Tiwary AK
Drug Dev Ind Pharm; 2012 Apr; 38(4):447-61. PubMed ID: 21954892
[TBL] [Abstract][Full Text] [Related]
20. Sustained release phenylpropanolamine hydrochloride from ATO 888 matrix.
Perez MA; Ghaly ES; Marti A
P R Health Sci J; 1993 Dec; 12(4):263-7. PubMed ID: 8140204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
